Jiuling Yang
Jiuling Yang has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- James R. Byrnes
Department of Pharmaceutical Chemistry, University of California, San Francisco
23 shared publications - Lisa L. Kirkemo
Department of Pharmaceutical Chemistry, University of California San Francisco
23 shared publications - Robert Blelloch
The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Center for Reproductive Sciences, University of California San Francisco, San Francisco, USA
23 shared publications - James A. Wells
University of California, San Francisco
22 shared publications - Cassandra D. Belair
Department of Urology, University of California San Francisco, San Francisco, California
21 shared publications - Hannah Driks
Department of Urology, University of California San Francisco, San Francisco, California
21 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S5: Combined loss of PVRL2 and PVR loss does not further inhibit tumor growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S5: Combined loss of PVRL2 and PVR loss does not further inhibit tumor growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S4: PVRL2 functions independently of PVRIG and TIGIT pathways.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S4: PVRL2 functions independently of PVRIG and TIGIT pathways.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S1: Proteomic analysis identifies PVRL2 on tumor-derived exosomes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S1: Proteomic analysis identifies PVRL2 on tumor-derived exosomes.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S3: PVRL2 regulates CD8 T cell and NK cell activation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S3: PVRL2 regulates CD8 T cell and NK cell activation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Table S1: Statistical analysis comparing the areas under curves (AUC) of tumor growth data between groups using an unpaired Student’s t test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Table S1: Statistical analysis comparing the areas under curves (AUC) of tumor growth data between groups using an unpaired Student’s t test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S2: PVRL2 promotes tumor growth through an immune-dependent mechanism.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S2: PVRL2 promotes tumor growth through an immune-dependent mechanism.
- Open Access
- 31 October 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (21) , 19503-19518
Discovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia
MDM2 has been pursued as an attractive therapeutic target for human cancers. Herein, we describe our discovery of MD-265 as a promising PROTAC MDM2 degrader and extensive in vitro and in vivo evaluations of its therapeutic potential and mechanism of action. MD-265 effectively depleted MDM2 protein in cancer cells at concentrations as low as 1 nM, leading to strong activation of p53 in cancer cells carrying wild-type p53. It selectively inhibited the growth of wild-type p53 leukemia cell lines and showed no activity in mutated p53 lines. MD-265 achieved persistent tumor regression in a leukemia xenograft model without causing any signs of toxicity and dramatically improved survival of mice in a disseminated leukemia model even with a weekly administration. MD-265 displayed an excellent intravenous PK profile in mice, rats, and dogs. MD-265 is a promising MDM2 degrader for advanced preclinical development for the treatment of human cancers.
- 31 October 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (21) , 19503-19518
Open AccessDiscovery of MD-265: A Potent MDM2 Degrader That Achieves Complete Tumor Regression and Improves Long-Term Survival of Mice with Leukemia
MDM2 has been pursued as an attractive therapeutic target for human cancers. Herein, we describe our discovery of MD-265 as a promising PROTAC MDM2 degrader and extensive in vitro and in vivo evaluations of its therapeutic potential and mechanism of action. MD-265 effectively depleted MDM2 protein in cancer cells at concentrations as low as 1 nM, leading to strong activation of p53 in cancer cells carrying wild-type p53. It selectively inhibited the growth of wild-type p53 leukemia cell lines and showed no activity in mutated p53 lines. MD-265 achieved persistent tumor regression in a leukemia xenograft model without causing any signs of toxicity and dramatically improved survival of mice in a disseminated leukemia model even with a weekly administration. MD-265 displayed an excellent intravenous PK profile in mice, rats, and dogs. MD-265 is a promising MDM2 degrader for advanced preclinical development for the treatment of human cancers.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Table S1: Statistical analysis comparing the areas under curves (AUC) of tumor growth data between groups using an unpaired Student’s t test.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Table S1: Statistical analysis comparing the areas under curves (AUC) of tumor growth data between groups using an unpaired Student’s t test.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S5: Combined loss of PVRL2 and PVR loss does not further inhibit tumor growth.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S5: Combined loss of PVRL2 and PVR loss does not further inhibit tumor growth.
- Open Access
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S4: PVRL2 functions independently of PVRIG and TIGIT pathways.
- 2 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways
Supplementary Figure S4: PVRL2 functions independently of PVRIG and TIGIT pathways.